US4897355A
(en)
|
1985-01-07 |
1990-01-30 |
Syntex (U.S.A.) Inc. |
N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
|
US5128257A
(en)
|
1987-08-31 |
1992-07-07 |
Baer Bradford W |
Electroporation apparatus and process
|
EP0398960B1
(de)
|
1988-01-21 |
1995-12-06 |
Massachusetts Institute Of Technology |
Molekültransport durch gewebe mit der verwendung von elektroporation
|
US6303121B1
(en)
|
1992-07-30 |
2001-10-16 |
Advanced Research And Technology |
Method of using human receptor protein 4-1BB
|
US6362325B1
(en)
|
1988-11-07 |
2002-03-26 |
Advanced Research And Technology Institute, Inc. |
Murine 4-1BB gene
|
ZA902710B
(en)
|
1989-05-22 |
1991-12-24 |
Univ Georgia Res Found |
Enzyme luminescence assay
|
US5279833A
(en)
|
1990-04-04 |
1994-01-18 |
Yale University |
Liposomal transfection of nucleic acids into animal cells
|
US5264618A
(en)
|
1990-04-19 |
1993-11-23 |
Vical, Inc. |
Cationic lipids for intracellular delivery of biologically active molecules
|
WO1991017424A1
(en)
|
1990-05-03 |
1991-11-14 |
Vical, Inc. |
Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
|
CA2019758C
(en)
|
1990-06-25 |
2001-09-04 |
Kevin L. Firth |
Improved electroporation device and method
|
US5137817A
(en)
|
1990-10-05 |
1992-08-11 |
Amoco Corporation |
Apparatus and method for electroporation
|
US5173158A
(en)
|
1991-07-22 |
1992-12-22 |
Schmukler Robert E |
Apparatus and methods for electroporation and electrofusion
|
US5304120A
(en)
|
1992-07-01 |
1994-04-19 |
Btx Inc. |
Electroporation method and apparatus for insertion of drugs and genes into endothelial cells
|
US5273525A
(en)
|
1992-08-13 |
1993-12-28 |
Btx Inc. |
Injection and electroporation apparatus for drug and gene delivery
|
US5318514A
(en)
|
1992-08-17 |
1994-06-07 |
Btx, Inc. |
Applicator for the electroporation of drugs and genes into surface cells
|
CA2146559A1
(en)
|
1992-10-23 |
1994-05-11 |
Melanie K. Spriggs |
Methods of preparing soluble, oligomeric proteins
|
GB9317380D0
(en)
|
1993-08-20 |
1993-10-06 |
Therexsys Ltd |
Transfection process
|
US5821332A
(en)
|
1993-11-03 |
1998-10-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Receptor on the surface of activated CD4+ T-cells: ACT-4
|
US6989434B1
(en)
|
1994-02-11 |
2006-01-24 |
Invitrogen Corporation |
Reagents for intracellular delivery of macromolecules
|
US5691188A
(en)
|
1994-02-14 |
1997-11-25 |
American Cyanamid Company |
Transformed yeast cells expressing heterologous G-protein coupled receptor
|
EP0769063A1
(de)
|
1994-06-27 |
1997-04-23 |
The Johns Hopkins University |
Gezielte freigabe genetischen materials
|
US5908635A
(en)
|
1994-08-05 |
1999-06-01 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method for the liposomal delivery of nucleic acids
|
US5484720A
(en)
|
1994-09-08 |
1996-01-16 |
Genentech, Inc. |
Methods for calcium phosphate transfection
|
US5830430A
(en)
|
1995-02-21 |
1998-11-03 |
Imarx Pharmaceutical Corp. |
Cationic lipids and the use thereof
|
ATE226641T1
(de)
|
1995-04-08 |
2002-11-15 |
Lg Chemical Ltd |
Humaner 4-1bb spezifischer humaner antikörper und diesen produzierende zellinie
|
US5981501A
(en)
|
1995-06-07 |
1999-11-09 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating plasmids in lipid bilayers
|
US6010613A
(en)
|
1995-12-08 |
2000-01-04 |
Cyto Pulse Sciences, Inc. |
Method of treating materials with pulsed electrical fields
|
US5849902A
(en)
|
1996-09-26 |
1998-12-15 |
Oligos Etc. Inc. |
Three component chimeric antisense oligonucleotides
|
BR9712278A
(pt)
|
1996-10-11 |
1999-08-31 |
Bristol Myers Squibb Co |
Processos e composições para imunomodulação
|
AU5734998A
(en)
|
1997-01-10 |
1998-08-03 |
Life Technologies, Inc. |
Embryonic stem cell serum replacement
|
DK0973928T3
(da)
|
1997-03-11 |
2010-08-09 |
Univ Minnesota |
DNA-baseret transposonsystem til indføring af nukleinsyre i DNA i en celle
|
GB9710809D0
(en)
|
1997-05-23 |
1997-07-23 |
Medical Res Council |
Nucleic acid binding proteins
|
US6475994B2
(en)
|
1998-01-07 |
2002-11-05 |
Donald A. Tomalia |
Method and articles for transfection of genetic material
|
US6312700B1
(en)
|
1998-02-24 |
2001-11-06 |
Andrew D. Weinberg |
Method for enhancing an antigen specific immune response with OX-40L
|
EP1060261B1
(de)
|
1998-03-02 |
2010-05-05 |
Massachusetts Institute of Technology |
Poly-zinkfinger-proteine mit verbesserten linkern
|
US6534261B1
(en)
|
1999-01-12 |
2003-03-18 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
US7013219B2
(en)
|
1999-01-12 |
2006-03-14 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
US20030104526A1
(en)
|
1999-03-24 |
2003-06-05 |
Qiang Liu |
Position dependent recognition of GNN nucleotide triplets by zinc fingers
|
US6794136B1
(en)
|
2000-11-20 |
2004-09-21 |
Sangamo Biosciences, Inc. |
Iterative optimization in the design of binding proteins
|
US7030215B2
(en)
|
1999-03-24 |
2006-04-18 |
Sangamo Biosciences, Inc. |
Position dependent recognition of GNN nucleotide triplets by zinc fingers
|
US7189705B2
(en)
|
2000-04-20 |
2007-03-13 |
The University Of British Columbia |
Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
|
US6627442B1
(en)
|
2000-08-31 |
2003-09-30 |
Virxsys Corporation |
Methods for stable transduction of cells with hiv-derived viral vectors
|
JP2004534721A
(ja)
|
2000-10-31 |
2004-11-18 |
ピーアール ファーマシューティカルズ,インク. |
生理活性分子の向上した送達のための方法及び組成物
|
US7550140B2
(en)
|
2002-06-13 |
2009-06-23 |
Crucell Holland B.V. |
Antibody to the human OX40 receptor
|
AU2003259294A1
(en)
|
2002-07-30 |
2004-02-16 |
Bristol-Myers Squibb Company |
Humanized antibodies against human 4-1bb
|
AU2004280623B2
(en)
|
2003-10-08 |
2010-12-02 |
Wilson Wolf Manufacturing, LLC |
Cell culture methods and devices utilizing gas permeable materials
|
US7288638B2
(en)
|
2003-10-10 |
2007-10-30 |
Bristol-Myers Squibb Company |
Fully human antibodies against human 4-1BB
|
CN101072578A
(zh)
|
2004-10-29 |
2007-11-14 |
南加州大学 |
用共刺激分子的联合癌症免疫疗法
|
DK2650020T3
(en)
|
2005-05-06 |
2017-01-16 |
Providence Health & Services - Oregon |
Trimeric OX40 immunoglobulin fusion protein and methods for applications.
|
US7596024B2
(en)
|
2006-07-14 |
2009-09-29 |
Semiconductor Energy Laboratory Co., Ltd. |
Nonvolatile memory
|
EP1894940A1
(de)
|
2006-08-28 |
2008-03-05 |
Apogenix GmbH |
TNF Superfamilie Fusionsproteine
|
CL2008000578A1
(es)
|
2007-02-27 |
2008-10-10 |
Genentech Inc |
Anticuerpo antagonista aislado anti-receptor ox40 humano; molecula de acido nucleico que lo codifica; vector y celula huesped; metodo de produccion; composicion que lo comprende; su uso para tratar trastornos mediados por ox40; y metodo para detectar
|
ES2560871T3
(es)
|
2007-07-10 |
2016-02-23 |
Apogenix Gmbh |
Proteínas de fusión de colectina de la superfamilia de TNF
|
CA2702028A1
(en)
|
2007-10-02 |
2009-04-09 |
Rxi Pharmaceuticals Corp. |
Tripartite rnai constructs
|
SI2851374T1
(sl)
|
2007-12-14 |
2017-08-31 |
Bristol-Myers Squibb Company |
Vezavne molekule k humanemu ox40 receptorju
|
WO2009102427A2
(en)
|
2008-02-11 |
2009-08-20 |
Rxi Pharmaceuticals Corp. |
Modified rnai polynucleotides and uses thereof
|
EP2310409A2
(de)
|
2008-06-17 |
2011-04-20 |
Apogenix GmbH |
Multimere tnf-rezeptoren
|
EP2604693B1
(de)
|
2008-07-21 |
2016-02-24 |
Apogenix GmbH |
Einkettige TNFSF-Moleküle
|
EP2949752B1
(de)
|
2008-09-22 |
2017-12-20 |
RXi Pharmaceuticals Corporation |
Selbstfreisetzende rnai-verbindungen von reduzierter grösse
|
WO2010042433A1
(en)
|
2008-10-06 |
2010-04-15 |
Bristol-Myers Squibb Company |
Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
|
ES2593049T3
(es)
|
2009-01-09 |
2016-12-05 |
Apogenix Ag |
Proteínas de fusión que forman trímeros
|
US20130115617A1
(en)
|
2009-12-08 |
2013-05-09 |
John R. Wilson |
Methods of cell culture for adoptive cell therapy
|
SG181559A1
(en)
|
2009-12-08 |
2012-07-30 |
Wolf Wilson Mfg Corp |
Improved methods of cell culture for adoptive cell therapy
|
US8956860B2
(en)
|
2009-12-08 |
2015-02-17 |
Juan F. Vera |
Methods of cell culture for adoptive cell therapy
|
CN106074591B
(zh)
|
2010-03-24 |
2020-01-14 |
菲奥医药公司 |
眼部症候中的rna干扰
|
CN110042099A
(zh)
|
2010-03-24 |
2019-07-23 |
菲奥医药公司 |
皮肤与纤维化症候中的rna干扰
|
RU2615143C2
(ru)
|
2010-03-24 |
2017-04-04 |
Адвирна |
Самодоставляющие PHKi соединения уменьшенного размера
|
JP6208580B2
(ja)
|
2010-05-17 |
2017-10-04 |
サンガモ セラピューティクス, インコーポレイテッド |
新規のdna結合タンパク質及びその使用
|
EP2580331A4
(de)
|
2010-06-14 |
2013-11-27 |
Univ Iowa State Res Found Inc |
Nukleaseaktivität des tal-effektors und des fusionsproteins foki
|
AU2011293558B2
(en)
|
2010-08-23 |
2014-07-31 |
Board Of Regents, The University Of Texas System |
Anti-OX40 antibodies and methods of using the same
|
CN105481983B
(zh)
|
2010-09-09 |
2021-09-03 |
辉瑞公司 |
4-1bb结合分子
|
US8962804B2
(en)
|
2010-10-08 |
2015-02-24 |
City Of Hope |
Meditopes and meditope-binding antibodies and uses thereof
|
RS61854B1
(sr)
|
2010-11-12 |
2021-06-30 |
Nektar Therapeutics |
Konjugati il-2 dela i polimera
|
US20120244133A1
(en)
|
2011-03-22 |
2012-09-27 |
The United States of America, as represented by the Secretary, Department of Health and |
Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
|
DK2694091T3
(da)
|
2011-04-05 |
2019-06-03 |
Cellectis |
Fremgangsmåde til fremstilling af kompakte tale-nukleaser og anvendelse heraf
|
US20140234320A1
(en)
|
2011-06-20 |
2014-08-21 |
La Jolla Institute For Allergy And Immunology |
Modulators of 4-1bb and immune responses
|
WO2013016600A2
(en)
|
2011-07-28 |
2013-01-31 |
The Trustees Of The University Of Pennsylvania |
Methods and reagents for diagnosing conditions and characterization of tumor cells associated with serous fluids
|
EP2748199B1
(de)
|
2011-08-23 |
2019-08-28 |
Board of Regents, The University of Texas System |
Anti-ox40-antikörper und verfahren zu deren verwendung
|
SG11201400527XA
(en)
|
2011-09-16 |
2014-04-28 |
Univ Pennsylvania |
Rna engineered t cells for the treatment of cancer
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
PT2768942T
(pt)
|
2011-10-17 |
2020-01-21 |
Massachusetts Inst Technology |
Entrega intracelular
|
CA2872504A1
(en)
|
2012-05-18 |
2013-11-21 |
Wilson Wolf Manufacturing Corporation |
A static animal cell culture and cell recovery
|
MX370265B
(es)
|
2012-05-25 |
2019-12-09 |
Cellectis |
Métodos para manipular por ingeniería genética célula t alogénica y resistente a inmunosupresores para inmunoterapia.
|
EP2855671B1
(de)
|
2012-06-05 |
2019-02-20 |
Cellectis |
Transcription activator-like effector (tale) fusionsprotein
|
NZ630851A
(en)
|
2012-06-08 |
2016-07-29 |
Alkermes Inc |
Fusion polypeptides comprising mucin-domain polypeptide linkers
|
JP2015519080A
(ja)
|
2012-06-11 |
2015-07-09 |
ウィルソン ウォルフ マニュファクチャリング コーポレイションWilson Wolf Manufacturing Corporation |
養子細胞療法のための改良型細胞培養方法
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
ES2598115T3
(es)
|
2012-12-12 |
2017-01-25 |
The Broad Institute, Inc. |
Ingeniería de sistemas, métodos y composiciones de guía optimizadas para manipulación de secuencias
|
AU2013359212B2
(en)
|
2012-12-12 |
2017-01-19 |
Massachusetts Institute Of Technology |
Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
|
US20140310830A1
(en)
|
2012-12-12 |
2014-10-16 |
Feng Zhang |
CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
|
US8993233B2
(en)
|
2012-12-12 |
2015-03-31 |
The Broad Institute Inc. |
Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
|
EP3825401A1
(de)
|
2012-12-12 |
2021-05-26 |
The Broad Institute, Inc. |
Systeme, verfahren und zusammensetzungen mit crispr-cas-komponenten zur sequenzmanipulation
|
ES2859678T3
(es)
|
2013-03-01 |
2021-10-04 |
Us Health |
Métodos para producir poblaciones enriquecidas de células T reactivas a tumores a partir de un tumor
|
MX2015013288A
(es)
|
2013-03-18 |
2016-04-07 |
Biocerox Prod Bv |
Anticuerpos anti-cd134 (ox40) humanizados y usos de los mismos.
|
US11311575B2
(en)
|
2013-05-13 |
2022-04-26 |
Cellectis |
Methods for engineering highly active T cell for immunotherapy
|
CN110564612B
(zh)
|
2013-06-24 |
2024-07-02 |
威尔逊沃夫制造公司 |
用于透气性细胞培养过程的封闭系统装置和方法
|
CN106061488B
(zh)
|
2013-12-02 |
2021-04-09 |
菲奥医药公司 |
癌症的免疫治疗
|
EP3083687A2
(de)
|
2013-12-17 |
2016-10-26 |
F. Hoffmann-La Roche AG |
Kombinationstherapie mit ox40-bindungsagonisten und pd-1-achsenbindungsantagonisten
|
EP3102604B1
(de)
|
2014-02-04 |
2020-01-15 |
Pfizer Inc |
Kombination eines pd-1-antagonisten und eines 4-1bb-agonisten zur behandlung von krebs
|
MY180750A
(en)
|
2014-06-11 |
2020-12-08 |
Polybiocept Ab |
Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
CN107922911A
(zh)
|
2015-07-09 |
2018-04-17 |
麻省理工学院 |
将物质递送至无核细胞
|
EP3365446A4
(de)
|
2015-10-19 |
2019-06-26 |
Phio Pharmaceuticals Corp. |
Gegen lange nichtcodierende rna gerichtete kleine selbstfreisetzende nukleinsäureverbindungen
|
CN116218916A
(zh)
|
2016-01-12 |
2023-06-06 |
Sqz生物技术公司 |
复合物的细胞内递送
|
MD3532607T2
(ro)
|
2016-10-26 |
2024-07-31 |
Iovance Biotherapeutics Inc |
Restimularea limfocitelor infiltrante în tumori crioconservate
|
EP3532078A4
(de)
*
|
2016-10-31 |
2020-06-03 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Künstliche antigenpräsentierende zellen zur expansion von immunzellen für die immuntherapie
|
TWI788307B
(zh)
*
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
EP3538130A4
(de)
|
2016-11-10 |
2020-06-03 |
Nektar Therapeutics |
Immuntherapeutisches tumorbehandlungsverfahren
|
WO2018129332A1
(en)
|
2017-01-06 |
2018-07-12 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
|
JP7250679B2
(ja)
|
2017-01-10 |
2023-04-03 |
ネクター セラピューティクス |
Tlr作動薬化合物のマルチアームポリマーコンジュゲート及び関連の免疫療法治療の方法
|
JOP20190224A1
(ar)
|
2017-03-29 |
2019-09-26 |
Iovance Biotherapeutics Inc |
عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
|
WO2018215936A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
|
EP3635097A1
(de)
|
2017-06-05 |
2020-04-15 |
Iovance Biotherapeutics, Inc. |
Verfahren zur verwendung von tumorinfiltrierenden lymphozyten in einem doppeltrefraktären melanom
|
KR102687649B1
(ko)
|
2017-08-03 |
2024-07-26 |
신톡스, 인크. |
증식성 질환 및 감염성 질환의 치료를 위한 사이토카인 접합체
|
SG11202004457XA
(en)
*
|
2017-11-17 |
2020-06-29 |
Iovance Biotherapeutics Inc |
Til expansion from fine needle aspirates and small biopsies
|
EP3737743A1
(de)
|
2018-01-08 |
2020-11-18 |
Iovance Biotherapeutics, Inc. |
Verfahren zur erzeugung von til-produkten, die für tumorantigenspezifische t-zellen angereichert sind
|
MA52533A
(fr)
|
2018-04-27 |
2021-03-03 |
Iovance Biotherapeutics Inc |
Procédé en circuit fermé pour l'amplification et l'edition de gènes de lymphocytes d'infiltration des tumeurs et leurs utilisations en immunothérapie
|
US11356582B2
(en)
|
2018-07-11 |
2022-06-07 |
Samsung Electro-Mechanics Co., Ltd. |
Camera module with gap maintaining member
|
JP2022514023A
(ja)
*
|
2018-12-19 |
2022-02-09 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
操作されたサイトカイン受容体対を使用して腫瘍浸潤リンパ球を拡大培養する方法及びその使用
|
EP3923974A4
(de)
|
2019-02-06 |
2023-02-08 |
Synthorx, Inc. |
Il-2-konjugate und verfahren zur verwendung davon
|
US20210038684A1
(en)
|
2019-06-11 |
2021-02-11 |
Alkermes Pharma Ireland Limited |
Compositions and Methods for Cancer Immunotherapy
|